MGF (Mechano Growth Factor)
Solid foundational research with 30 studies establishing its role in muscle repair, but the complete absence of randomized controlled trials means we're still missing the gold standard evidence for therapeutic applications.
Primarily studied by muscle physiology researchers investigating exercise-induced muscle damage, satellite cell biology, and potential treatments for muscle wasting conditions.
Since Feb 2026
30 total, 15 human
What is MGF (Mechano Growth Factor)?
When muscles experience mechanical stress or damage, they release a specialized variant of insulin-like growth factor called mechano growth factor. This locally-produced signaling molecule appears to coordinate the early stages of muscle tissue repair, making it a focus for researchers studying muscle regeneration and athletic recovery. Unlike its parent molecule IGF-1, MGF seems to have evolved specifically to respond to physical tissue damage.
MGF works by binding to receptors on dormant satellite cells—essentially muscle stem cells that sit quietly along muscle fibers until needed. When activated by MGF, these cells wake up, multiply, and begin fusing with damaged muscle tissue to rebuild and strengthen it. Think of MGF as a molecular alarm system that not only detects muscle damage but also recruits the cellular repair crew to fix it.
What the Research Shows
While 30 studies provide good mechanistic understanding and 15 human studies offer real-world context, the lack of any randomized controlled trials represents a significant gap in clinical evidence.
The literature review identified 30 total studies (17 human studies, 0 randomized controlled trials) demonstrating that MGF functions as a mechanically-sensitive IGF-1 isoform that regulates cartilage homeostasis, promotes muscle repair through satellite cell activation and protein synthesis, and enhances neural survival under adverse conditions such as hypoxia and inflammation. These findings suggest MGF acts as a tissue-specific repair factor in response to mechanical stimuli and injury, though the absence of RCTs indicates evidence is primarily observational or preclinical in nature.
Notable Studies
Sha Y, Zhang B, Chen L et al. · Int J Mol Sci (2022)
Animal · 4 weeks
Sha Y, Cai W, Mohanad Khalid A et al. · Int Immunopharmacol (2021)
Animal · 6 weeks
Song Y, Xu K, Yu C et al. · J Tissue Eng Regen Med (2018)
Animal · 2 weeks
Luo Z, Jiang L, Xu Y et al. · Biomaterials (2015)
Animal · 2 months
Peña JR, Pinney JR, Ayala P et al. · Biomaterials (2015)
Animal · 10 weeks
Reported Benefits
Regulatory Status
Last verified: Feb 2026
Related Peptides
This information is for research purposes only and does not constitute medical advice. Always consult a licensed physician before using any peptides.